Altimmune Inc [NASDAQ: ALT] surged by $0.3 during the normal trading session on Thursday and reaching a high of $4.185 during the day while it closed the day at $3.87.
Altimmune Inc stock has also gained 4.88% of its value over the past 7 days. However, ALT stock has declined by -42.92% in the 3 months of the year. Over the past six months meanwhile, it has lost -33.39% and lost -48.94% year-on date.
The market cap for ALT stock reached $341.56 million, with 88.26 million shares outstanding and 87.39 million shares in the current float. Compared to the average trading volume of 5.47M shares, ALT reached a trading volume of 6485227 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Altimmune Inc [ALT]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ALT shares is $18.44 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ALT stock is a recommendation set at 1.60. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Goldman have made an estimate for Altimmune Inc shares, keeping their opinion on the stock as Sell, with their previous recommendation back on July 10, 2025. While these analysts kept the previous recommendation, William Blair raised their target price to Mkt Perform. The new note on the price target was released on February 28, 2025, representing the official price target for Altimmune Inc stock. Previously, the target price had yet another raise to $18, while Stifel analysts kept a Buy rating on ALT stock.
The Price to Book ratio for the last quarter was 2.04, with the Price to Cash per share for the same quarter was set at 2.08.
ALT stock trade performance evaluation
Altimmune Inc [ALT] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 4.88. With this latest performance, ALT shares gained by 6.91% in over the last four-week period, additionally sinking by -33.39% over the last 6 months – not to mention a drop of -46.32% in the past year of trading.
Altimmune Inc [ALT]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Altimmune Inc [ALT] shares currently have an operating margin of -471850.00% and a Gross Margin at -545.00%. Altimmune Inc’s Net Margin is presently recorded at -438730.00%.
Altimmune Inc (ALT) Capital Structure & Debt Analysis
According to recent financial data for Altimmune Inc. ( ALT), the Return on Equity (ROE) stands at -55.91%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -48.25%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Altimmune Inc’s Return on Invested Capital (ROIC) is -49.58%, showcasing its effectiveness in deploying capital for earnings.
Altimmune Inc (ALT) Efficiency & Liquidity Metrics
Based on Altimmune Inc’s (ALT) latest financial statements, the Debt-to-Equity Ratio is 0.10%, indicating its reliance on debt financing relative to shareholder equity.
Altimmune Inc (ALT) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Altimmune Inc. (ALT) effectively leverages its workforce, generating an average of -$1487288.14 per employee. The company’s liquidity position is robust, with a Current Ratio of 20.41% and a Quick Ratio of 20.41%, indicating strong ability to cover short-term liabilities.
Earnings per share (EPS) analysis for Altimmune Inc [ALT] stock
With the latest financial reports released by the company, Altimmune Inc posted -0.32/share EPS, while the average EPS was predicted by analysts to be reported at -0.36/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 0.04. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ALT. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Altimmune Inc go to 5.47%.
Altimmune Inc [ALT]: Institutional Ownership
There are presently around $43.33%, or 43.66%% of ALT stock, in the hands of institutional investors. The top three institutional holders of ALT stocks are: BLACKROCK INC. with ownership of 5.32 million shares, which is approximately 7.5025%. VANGUARD GROUP INC, holding 4.91 million shares of the stock with an approximate value of $$32.63 million in ALT stocks shares; and VANGUARD GROUP INC, currently with $$26.0 million in ALT stock with ownership which is approximately 5.5119%.
